Craif has created a powerful platform to unveil cellular communications by exosomal enrichment. We are a custom solutions provider offering unique expertise and services that help solve complex clinical questions on behalf of our partners.
Our device captures urinal exosomes by electric interaction with nanowires in a microfluid. By using our technology, we can extract and measure urinal miRNAs and their expression patterns comprehensively. While conventional methods (e.g., ultracentrifugation) can capture only 15-20% of urinary exosomes despite hours of preparation, our ZnO nanowire device can collect more than 99% of the exosomes in 40 minutes.
Understanding the cellular communication enable various applications
High-throughput (HTS) and high-content screening (HCS) of exosomal biomarkers to identify predictive biomarkers, patient stratification, and MRD detection
HTS and HCS of biofluids from patients to elucidate disease mechanisms and potential targets
HTS and HTC of cell culture supernatants to identify key MoA of cell therapies and metrics for quality control
End to end research services provided
by interdisciplinary team of experts
Rapidly identifying more than a thousand biomarkers from a single urine draw
Harnessing machine learning to develop classifier of disease/non-disease
Identifying key biomarkers and revealing physiological insights
Identifying NASH-specific microRNA profiles by analyzing urine
Our technology platform can be applied not only to cancer but also non-cancer diseases
enables us to understand the unique signature of miRNA expression
are revealed by robust detection technology
are elucidated by comprehensive analysis
Major Japanese pharmaceutical company(Undisclosed)
Major Japanese manufacturer(Undisclosed)
